Evoke Pharma Inc financial data

Symbol
EVOK on Nasdaq
Location
Solana Beach, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 145% % 21%
Quick Ratio 5% % -11%
Debt-to-equity 218% % -54%
Return On Equity -101% % 69%
Return On Assets -32% % 43%
Operating Margin -36% % 47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,722,409 shares 16%
Common Stock, Shares, Outstanding 1,722,409 shares 92%
Entity Public Float $4,600,000 USD -13%
Common Stock, Value, Issued $172 USD 93%
Weighted Average Number of Shares Outstanding, Basic 2,557,408 shares 83%
Weighted Average Number of Shares Outstanding, Diluted 2,557,408 shares 83%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $14,424,652 USD 67%
Operating Income (Loss) $5,191,981 USD 12%
Nonoperating Income (Expense) $312,209 USD 15%
Net Income (Loss) Attributable to Parent $5,226,128 USD 19%
Earnings Per Share, Basic 0 USD/shares 98%
Earnings Per Share, Diluted 0 USD/shares 98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $11,576,010 USD 2.1%
Inventory, Net $599,908 USD 22%
Other Assets, Current $33,708 USD -7.4%
Assets, Current $15,536,407 USD 11%
Operating Lease, Right-of-Use Asset $106,714 USD
Other Assets, Noncurrent $6,312 USD
Assets $15,649,433 USD 11%
Employee-related Liabilities, Current $770,915 USD 31%
Liabilities, Current $12,240,816 USD 25%
Operating Lease, Liability, Noncurrent $46,381 USD
Liabilities $12,287,197 USD 26%
Retained Earnings (Accumulated Deficit) $132,824,994 USD -4.1%
Stockholders' Equity Attributable to Parent $3,362,236 USD -23%
Liabilities and Equity $15,649,433 USD 11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $997,509 USD 61%
Net Cash Provided by (Used in) Financing Activities $24,999 USD -100%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 1,722,409 shares 92%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $972,510 USD -120%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11,576,010 USD 2.1%
Deferred Tax Assets, Valuation Allowance $28,230,000 USD -2.4%
Deferred Tax Assets, Gross $28,266,000 USD -2.3%
Operating Lease, Liability $112,349 USD
Lessee, Operating Lease, Liability, to be Paid $120,516 USD
Operating Lease, Liability, Current $65,968 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $20,551 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $80,207 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $8,167 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $20,551 USD
Deferred Tax Assets, Operating Loss Carryforwards $25,012,000 USD 5.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $3,273,000 USD 0%
Operating Lease, Payments $70,803 USD -15%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense $500,001 USD -0.27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%